论文部分内容阅读
目的观察并探讨参麦注射液联合化疗对乳腺癌患者减毒增效的临床疗效。方法将60例乳腺癌术后辅助化疗患者随机分为治疗组和对照组各30例。对照组仅予化疗,治疗组在对照组的基础上加用参麦注射液,疗程为1周,比较2组临床疗效,并记录药物不良反应。结果与对照组及健康对照组相比,观察组可有效调节化疗后乳腺癌患者外周淋巴细胞群落,并可改善化疗后乳腺癌患者生活质量,差异具有统计学意义(P<0.05)。结论参麦注射液对乳腺癌术后辅助化疗均有减毒增效的作用。
Objective To observe and discuss the clinical curative effect of Shenmai injection combined with chemotherapy on attenuated and synergistic effect of breast cancer patients. Methods Sixty patients with postoperative adjuvant chemotherapy for breast cancer were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was given only chemotherapy. The treatment group was given Shenmai injection on the basis of the control group for one week. The clinical efficacy was compared between the two groups and the adverse drug reaction was recorded. Results Compared with the control group and the healthy control group, the observation group could effectively adjust the peripheral lymphocyte population in patients with breast cancer after chemotherapy and improve the quality of life of the patients with breast cancer after chemotherapy. The difference was statistically significant (P <0.05). Conclusion Shenmai injection has the effect of reducing the toxicity and increasing the efficiency of postoperative adjuvant chemotherapy for breast cancer.